Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Maggie Yuen, Chief Financial Officer of Penumbra Inc. (PEN), reported insider transactions on Form 4 covering trades dated August 13 and August 15, 2025. On August 13 she disposed of 2,000 shares at $250 per share pursuant to a Rule 10b5-1 trading plan. On August 15 she acquired 724 shares at $158.30 and executed a stock option for 724 shares with a $158.30 exercise price that vests and is exercisable through December 15, 2029. Following these transactions she beneficially owns 13,667 shares in total, of which some shares are subject to vesting and 86 were purchased under the company ESPP on May 19, 2025.
The filing is signed by an attorney-in-fact and explicitly states the August 13 sale was made under a 10b5-1 plan; it also notes all option shares reported are vested and exercisable. No additional financial results or company guidance are included.
Penumbra director Arani Bose reported sales of common stock on 08/13/2025 executed under a Rule 10b5-1 trading plan. The filing shows two reported disposals totaling 12,000 shares sold at weighted average prices of $250.45 and $251.27, respectively, with the aggregated proceeds reflected by those weighted averages.
After the transactions the reporting person retained 3,455 shares held directly and 290,261 shares held indirectly through Bose Family Holdings II, LLC; a portion of directly held shares remains subject to vesting. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Penumbra director Thomas Wilder sold 372 shares of Penumbra common stock on 08/12/2025 at $240.16 per share under a Rule 10b5-1 trading plan. After the reported sale, the filing shows the reporting person beneficially owns 372 shares directly and 4,506 shares indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006. The Form 4 notes a portion of the directly held shares are subject to vesting.
The filing states transfers between direct and indirect holdings through the family trust are treated as changes in form of ownership exempt under Rule 16a-13.
Penumbra Inc. (PEN) EVP, General Counsel & Secretary Johanna Roberts reported multiple sales of Penumbra common stock executed on 08/11/2025 pursuant to a Rule 10b5-1 trading plan. The filing shows five transactions totaling 600 shares, with reported weighted average prices ranging from $237.10 to $240.91 and execution price ranges disclosed between $236.83 and $240.78. Following these disposals reported beneficial ownership declined from 66,039 shares to 65,457 shares. The filer notes that a portion of the shares is subject to vesting and that full trade-level details will be provided to the SEC staff, the issuer or a security holder upon request.
Penumbra, Inc. submitted a Form 144 notifying a proposed sale under Rule 144 of 12,000 shares of its common stock through J.P. Morgan Securities LLC. The filing reports an aggregate market value of $2,982,600 for the shares, an approximate sale date of 08/13/2025, and lists the securities exchange as the NYSE. The filing also shows 38,999,129 shares outstanding.
The 12,000 shares were acquired on 06/22/2004 as founder stock from the issuer. The filer reports "Nothing to Report" for securities sold during the past three months and includes the standard representation that the selling person does not know of undisclosed material adverse information about the issuer.
Penumbra, Inc. submitted a Form 144 reporting a proposed sale of 2,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $500,000. The filing lists 38,999,129 shares outstanding and specifies the approximate sale date as 08/13/2025 on the NYSE. The notice shows no securities sold in the past three months under the provided "Nothing to Report" entry.
The 2,000 shares to be sold match earlier restricted stock acquisitions recorded in the filing: 338 shares on 12/16/2020, 612 on 11/15/2022, 726 on 12/16/2022, and 324 on 03/15/2024, totaling 2,000 shares. The filer makes the required representation regarding material nonpublic information and mentions Rule 10b5-1 instructions if applicable.
Penumbra, Inc. filed a Form 144 notifying an intended sale of 372 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $89,339.52. The filing lists 38,999,129 shares outstanding and an approximate sale date of 08/12/2025 on the NYSE. The 372 shares were acquired as restricted stock in two grants of 186 shares each, dated 03/31/2025 and 06/30/2025, with payment noted as Not Applicable. The filing reports Nothing to Report for securities sold in the past three months and includes the seller's representation that they do not possess undisclosed material adverse information, with reference to Rule 10b5-1 plan language.
Adam Elsesser, CEO and President of Penumbra Inc. (PEN), reported an option exercise and planned sales under a Rule 10b5-1 trading plan on 08/06/2025. He acquired 27,976 shares by exercising options at a $30 conversion price and sold five blocks totaling 16,030 shares at weighted-average prices ranging from $236.78 to $240.56. Direct beneficial ownership decreased from 174,234 to 158,204 shares; an additional 577,582 shares are held indirectly by the Siegel/Elsesser Revocable Trust. The filing notes the sales were effected to satisfy exercise price and tax withholding obligations and were implemented pursuant to the 10b5-1 plan.